- Record: found
- Abstract: found
- Article: not found
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
George K K Lau
1 ,
Teerha Piratvisuth ,
Kang Xian Luo ,
Patrick Marcellin ,
Satawat Thongsawat ,
Graham Cooksley ,
Edward Gane ,
Michael W Fried ,
Wan Cheng Chow ,
Seung Woon Paik ,
Wen Yu Chang ,
Thomas Berg ,
Robert Flisiak ,
Philip McCloud ,
Nigel Pluck
Jun 30 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.